A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Shares of Centene are trading lower on Thursday, hitting a new 52-week low. A rival's profit warning fueled investor anxiety over government-sponsored healthcare.
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
The health insurer now expects its adjusted net income per diluted share to be approximately $30.00, down from its previous guidance of $34.15 to $34.85.
UnitedHealth extended its 15-year earnings beat streak in 2024 with $3.3 billion in asset sales, raising questions about financial reporting and deal transparency.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
NVDA stock hit a $4 trillion market cap, but tariff concerns brought back the bears; next week brings a slew of economic data and the start of earnings season
Centene just crashed. But, price target updates signal the selloff is overdone, with 50% upside in play. However, the "Big Beautiful Bill" is another curveball.
UnitedHealth, Centene, and Elevance suffered steep market cap losses amid earnings guidance withdrawals and potential Medicaid changes tied to new legislation.
